Appendix 4D and FY26 Half Year Financial Report
Filed with ASX · · 19 pages · English
Summary by 6ix AI
It reports a decline in revenue and a loss attributable to the owners, with significant decreases in both categories compared to the previous year. The report also highlights a strategic shift in operations and cost management, including changes in board composition and marketing strategies. No dividends were declared during this period, and the company is facing uncertainties regarding its ability to continue as a going concern.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Hydration Pharmaceuticals Company Limited on 6ix
Story so far
Earlier from Hydration Pharmaceuticals
- Q2 FY26 Quarterly Activities Report (App 4C)
- Capital raising, board renewal and management changes
- Q1 FY26 Quarterly Activities Report (App 4C)
- Appendix 4E and Annual Report
- Cost savings implemented & inventory replenishment completed
Later from Hydration Pharmaceuticals
- July and August 2026 Trading Update
- Rights Issue and UMP Share Sale Facility
- Prospectus - Non Renounceable Rights Issue
- Q3 FY26 Quarterly Activities Report (App 4C)
Follow Hydration Pharmaceuticals into a list and get an email when it puts out news.
Follow Hydration Pharmaceuticals